AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting

November 6, 2019

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Nov 6, 2019--

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its QIAseq NGS portfolio to offer a one-day workflow for simultaneous preparation of DNA and RNA libraries using next-generation sequencing (NGS) technologies.

The new QIAseq ® Multimodal Panels are the only solution to offer a consolidated workflow to simultaneously detect DNA variants, RNA fusions and gene expression levels from a single sample, with an input as low as 10 ng of total nucleic acid. This unmatched low-input solution reduces a typical 2-3 day workflow to approximately only nine hours by eliminating the need for two separate time-consuming, inefficient and costly workflows for library preparation from separate DNA and RNA samples. Both libraries are generated from the same sample input, sample utilization and, in turn, sampling-induced bias is also reduced. This enables labs to conserve samples of limited availability for further downstream applications.

The new QIAseq products will be showcased this week together with QIAGEN’s full range of Sample to Insight solutions for molecular oncology research and diagnostics at the Association for Molecular Pathology (AMP) 2019 Annual Meeting in Baltimore, Maryland.

For more information about QIAGEN’s presence at AMP 2019, please visit amp.qiagen.com.

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20191105006299/en/

CONTACT: Investor Relations

John Gilardi

+49 2103 29 11711

Phoebe Loh

+49 2103 29 11457

e-mail:ir@QIAGEN.com

Public Relations

Thomas Theuringer

+49 2103 29 11826

e-mail:pr@QIAGEN.com

KEYWORD: MARYLAND SWITZERLAND UNITED STATES AUSTRIA NORTH AMERICA EUROPE GERMANY

INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: QIAGEN

Copyright Business Wire 2019.

PUB: 11/06/2019 01:30 AM/DISC: 11/06/2019 01:30 AM

http://www.businesswire.com/news/home/20191105006299/en